Serum Institute Files Rs 100 Crore Defamation Case Against The Volunteer Who Said Vaccine Made Him IllNovember 30, 2020 14:54
(Image source from: pharmaceutical-technology.com)
A volunteer of Serum Institute’s of India (SII) on going COVID vaccine trials says the vaccine caused “virtual neurological breakdown” post the taking the dose. The institute said volunteer’s claims are “malicious and misconceived” allegations and said it will file a 100 crore defamation case against the man.
SII issued a statement “absolutely no correlation with the vaccine trial and the medical condition of the volunteer". The Pune based pharmaceutical company sympathized the volunteer’s medical condition in the same statement.
The volunteer was prior informed by the company that his medical condition is independent of the vaccine trial. In spite of clarifying it, he still published his wrong claims which could damage the company’s reputation, says SII.
The volunteer of 40 Year old from Chennai was a part of third phase of the COVID vaccine trial and he suffered "a serious adverse event after being administered the under-trial vaccine". And he claimed Rs 5 crore compensation from the SII. The volunteer underwent the vaccine test at Chennai’s Sri Ramachandra Institute of Higher Education on October 1.
He filed a legal notice on November 21 in which he mentioned that, “severe headaches, total behaviour change and irritation towards sound and light”. The notice says, he could not recognize anyone or speak. He experienced the abnormal condition after 10 days of vaccine test.
The man was discharged from the Hospital on October 26 but suffered “acute encephalopathy” as per the claimed notice which is entitled as “an extreme side effect of the test vaccine”.
The man’s claim is will be investigated by the The Drugs Controller General of India (DCGI) and an ethics committee at the Sri Ramachandra Institute.
COVID vaccine from SII is one of the candidates which reached latter stages with global testing. The CEO Adar Poonawalla of SII met PM Modi on Saturday and said the company is going to apply for an emergency use license for Covishield.
By Ramya C